LBNEs loaded with mRNA vaccines and PD‐L1 inhibitors induced tumor‐specific T cell responses in renal cell carcinoma models and overcame immune escape.[149] Furthermore, LBNEs co‐loaded with sorafenib and the hypoxia‐activating prodrug T‐302 can synergistically sensitize the hypoxic tumor microenvironment and reverse drug resistance.[150]. Here, CD274 is linked to neoplasm.